Keros Therapeutics (KROS) Receivables: 2021-2025
Historic Receivables for Keros Therapeutics (KROS) over the last 2 years, with Sep 2025 value amounting to $3.5 million.
- Keros Therapeutics' Receivables rose 800.00% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.3 million, marking a year-over-year increase of 5069.65%. This contributed to the annual value of $2.7 million for FY2024, which is 1817.48% up from last year.
- According to the latest figures from Q3 2025, Keros Therapeutics' Receivables is $3.5 million, which was down 77.92% from $15.8 million recorded in Q2 2025.
- Keros Therapeutics' 5-year Receivables high stood at $18.0 million for Q4 2021, and its period low was $4,000 during Q2 2024.
- For the 3-year period, Keros Therapeutics' Receivables averaged around $5.0 million, with its median value being $1.6 million (2024).
- Data for Keros Therapeutics' Receivables shows a peak YoY skyrocketed of 395,300.00% (in 2025) over the last 5 years.
- Quarterly analysis of 4 years shows Keros Therapeutics' Receivables stood at $18.0 million in 2021, then reached $143,000 in 2023, then spiked by 1,817.48% to $2.7 million in 2024, then soared by 800.00% to $3.5 million in 2025.
- Its last three reported values are $3.5 million in Q3 2025, $15.8 million for Q2 2025, and $17.3 million during Q1 2025.